Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension

Wilding, John; L. Batterham, Rachel; J. Davies, Melanie; F. Van Gaal, Luc; Kandler, Kristian; Konakli, Katerina; Lingvay, Ildiko; McGowan, Barbara; Kalaycı Oral, Tuğçe; Rosenstock, Julio; A. Wadden, Thomas; Wharton, Sean; Yokote, Koutaro; F. Kushner, Robert; 1 Study Group, STEP

doi:10.1111/dom.14725

Public

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

Published in Diabetes Obesity and Metabolism • Apr 19, 2022

Authors:

John Wilding

Rachel L. Batterham

Melanie J. Davies

Abstract

AIM: To explore changes in body weight and cardiometabolic risk factors after treatment withdrawal in the STEP 1 trial extension. MATERIALS AND METHODS: with ≥ 1 weight-related co-morbidity) without diabetes to 68 weeks of once-weekly subcutaneous semaglutide 2.4 mg (including 16 weeks of dose escal...

Subject

Semaglutide

Medicine

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!